Caring for wounds is both art and science. You provide the dedication and skill to your patients – 3M provides unparalleled solutions developed by empathetic experts who apply science to your healthcare challenges. But in this time of the COVID-19 pandemic, healthcare treatments may have been delayed, resulting in the loss of precious healing time. 3M products can help promote healing and bring the focus back to wound healing with interventions such as negative pressure wound therapy and advanced wound care options that may reduce the risk of infections, reduce the risk of wound complications and get patients back to their lives.
Now more than ever, patients need reassurance that they don’t have to manage their wounds alone for recovery and healing. And clinicians need a trusted partner that goes beyond selling products to providing trusted solutions and best-in-class service. 3M gives you the protocols, proven portfolios and expert support that enable you to focus on delivering the clinical and economic outcomes you need. When you’re there for your patients, 3M is here for you, helping to bring certainty to uncertain times.
COVID- 19 has dramatically changed the healthcare landscape for you and your wound care patients. Now, as your patients seek advanced modalities to help them get back to their lives, you can give them the best possible advantage. As the leader in out-of-hospital negative pressure wound therapy (NPWT), 3M delivers the innovative wound care technology and evidence-based outcomes you need with the safety and confidence your patients can trust.
When COVID-19 limits office visits, you need powerful allies to help keep your patients’ healing on track. That’s why we offer a comprehensive portfolio of advanced wound care solutions. From gels that destroy biofilm to dressings that can provide an effective barrier to bacterial contamination, 3M gives you the solutions and support your wound care patients need to encourage healing and help them get back to their lives.
Venous leg ulcers (VLUs) are the most common type of lower extremity wound, afflicting approximately 1% of the western population during their lifetime.19 With the onset of COVID-19, outpatient clinic visits dropped dramatically and some VLU patients were no longer receiving their weekly assessments and treatment.
Delays and interruptions in care can cause wound healing to stall and deteriorate. You can help patients stay on track by focusing on best practices for skin and wound management and incorporating compression therapy as the gold standard of VLU care.
Today, more than ever, your patients deserve innovative 3M skin protectants, wound care dressings and compression systems to help bring the focus back to wound healing and get them back on their feet.
V.A.C.® Therapy has been shown to be a successful way to manage wounds for the past 25 years. Extensive and early use of negative pressure wound therapy (NPWT) can be beneficial in helping prevent wound healing complications and helping to support healing.1
V.A.C.® Therapy has been associated with:
Studies have shown that faster healing rates may result from earlier use of Advanced Wound Dressing products, which may reduce rates of infection, inflammation and wound chronicity.1,2 Don’t wait. Implement 3M Solutions to manage biofilm and bioburden and be certain you are helping your patients.
BlastX™Antimicrobial Wound Gel is a breakthrough antimicrobial wound gel that deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment.
KERRACEL™ Ag Dressing is a gelling fiber dressing that contains Ag OXYSALTS™ Technology to help manage infected, exuding wounds.
PROMOGRAN PRISMA™ Matrix is comprised of a sterile, freeze-dried composite of 44% Oxidized Regenerated Cellulose (ORC), 55% Collagen, and 1% Silver-ORC, which contains 25% w/w ionically bound silver, a well-known antimicrobial agent.
Early initiation of V.A.C.® Therapy on acute and chronic wounds has been shown to reduce length of stay days in acute care, long term acute care, and home health.12-16*
3M offers a range of specialized NPWT solutions to support your individual facility and patient needs
The ACTIV.A.C.™ Therapy System was specifically developed for the mobile wound care patient, to help them resume their activities of daily living while still receiving the proven benefits of portable V.A.C.® Therapy.
The SNAP™ Therapy System is a unique and convenient disposable negative pressure wound therapy (NPWT) solution, ideal for patients that might benefit from silent, hidden, and wearable NPWT.
Protect skin: protect periwound skin areas exposed to moisture, friction and shear
Manage biofilm/bioburden that is present in 90% of chronic wounds, including VLUsr
Optimize wound environment and manage exudate
Provide therapeutic compression therapy. Compression therapy is the gold standard of care for management of VLUs and has been shown to increase the rate of healing as compared to healing rates without the use of compression.
Resources for practice and treatment of wound care patients
Watch and listen to a variety of subject matter experts about the impact of COVID-19 on the practice and treatment of wound care patients. Click on the videos below to learn more:
As your facility prepares for a new business as usual, 3M is dedicated to providing you with the information needed to help keep people protected at every touchpoint.
Find all medical respiratory protection resources in one place, including information about protection options, PPE and skin protection, optimizing your supply and extended use and limited re-use guidance.
*Early NPWT was defined for acute wounds as treatment initiated within the first 7 days from the first wound treatment date and within 30 days for chronic wounds; late NPWT initiation occurred after this time. A secondary analysis was conducted on a sub-set of patients where Charlson Co-morbidity Index Scores ≤5, to assess Early vs. Late cost differences by wound type, excluding the sickest patients with significant non-wound long-term care costs; this cohort represented 80% of the wounds.
1.Banasiewicz T, Becker R, Banasiewicz A, et al. Prevention and therapy of acute and chronic wounds using NPWT devices during the COVID-19 pandemic, recommendation from the NPWT working group. Negative Pressure Wound Therapy Journal. 2020;(7)4-9.
2.Page JC, Newswander B, Schwenke DC, Hansen M, Ferguson J. Retrospective analysis of negative pressure wound therapy in open foot wounds with significant soft tissue defects. Advances in Skin and Wound Care. 2004;17:354-364.
3.Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. Impact of vacuum-assisted closure (VAC) therapy on clinical outcomes of patients with sternalwound infections: a meta-analysis of non-randomized studies. PLoS One. 2013 May 31;8(5):e64741.
4.Scherer LA, Shiver S, Chang M, Meredith JW, Owings JT. The vacuum assisted closure device: a method of securing skin grafts and improving graft survival. Arch Surg. 2002;137:930-934.
5.Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31:631-636.
6.Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005;366:1704-1710.
7.Monsen C, Acosta S, Mani K, Wann-Hansson C. A randomised study of NPWT closure versus alginate dressings in peri-vascular groin infections: quality of life, pain and cost. J Wound Care. 2015;24:252-260.
8.Ozturk E, Ozguc H, Yilmazlar T. The use of vacuum assisted closure therapy in the management of Fournier's gangrene. Am J Surg. 2009;197:660-665.
9.Sinha K, Chauhan VD, Maheshwari R, Chauhan N, Rajan M, Agrawal A. Vacuum assisted closure therapy versus standard wound therapy for open musculoskeletal injuries. Adv Orthop. 2013;2013:245940.
10.Nord D. Efficacy and cost-efficiency in wound care. The German V.A.C. experience. Journal of Wound Technology. 2008;42-45.
11.Dalla Paola L, Carone A, Ricci S, Russo A, Ceccacci T, Ninkovic S. Use of vacuum assisted closure therapy in the treatment of diabetic foot wounds. Journal of Diabetic Foot Complications. 2010;2:33-44.
12.Baharestani MM. Driver VR. Optimizing clinical and cost effectiveness with early intervention of V.A.C.® Therapy. Ostomy Wound Manage. 2008;54(11 Suppl):1-15
13.Baharestani MM, Houliston-Otto DB, Barnes S. Early versus late initiation of negative pressure wound therapy: examining the impact home care length of stay. Ostomy Wound Manage. 2008; 54(11 Suppl):48-53.
14.Driver VR, de Leon JM. Health economic implications for wound care and limb preservation. J Managed Care Med. 2008; 1(11):13-19.
15.Miller-Mikolajczyk C, MStat RJ. Real world use: comparing early versus late initiation of negative pressure wound therapy on wound surface area reduction in patients at wound care clinics. Poster presented at The Wound Ostomy and Continence Nurses Society Annual Conference, June 22-26, 2013. Seattle, Washington.
16.Kaplan M, Daly D, Stemkowski S. Early intervention of negative pressure wound therapy using vacuum-assisted closure in trauma patients: impact on hospital length of stay and cost. Adv Skin Wound Care. 2009;3(22):128-132.
17.Cullen B, Gibson M, Nisbet L. Early adoption of collagen/ORC therapies improves clinical outcomes. Poster presented at: World Union of Wound Healing Societies (WUWHS); 2012; Japan.
18.2. Snyder RJ, Cardinal M, Dauphinee DM, Stavosky J. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. Ostomy Wound Manage. 2010;56(3)44-50.
19.O’Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012